BC
RPRX icon

Bridgefront Capital’s Royalty Pharma RPRX Stock Holding History

Bridgefront Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-48,362
Closed -$2.32M – 708
2026
Q1 		$2.32M Buy
+48,362
New +$2.12M 0.58% 31
2025
Q1 		– Sell
-12,205
Closed -$311K – 814
2024
Q4 		$311K Buy
+12,205
New +$324K 0.11% 348
2023
Q3 		– Sell
-9,419
Closed -$290K – 577
2023
Q2 		$290K Buy
+9,419
New +$319K 0.16% 262
2023
Q1 		– Sell
-6,041
Closed -$239K – 560
2022
Q4 		$239K Buy
+6,041
New +$252K 0.17% 260

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgefront Capital's RPRX Position: Q2 2026 in Review

Bridgefront Capital sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 48,362 shares — an estimated $2.32M sold.

Bridgefront Capital first reported a position in RPRX in Q4 2022 and held it in 4 quarters. The position peaked at $2.32M in Q1 2026. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Bridgefront Capital reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 48,362 Royalty Pharma shares in Q2 2026, an estimated $2.32M.
  • Bridgefront Capital first reported a position in Royalty Pharma in Q4 2022 and held it in 4 quarters.
  • Bridgefront Capital's Royalty Pharma position peaked at $2.32M in Q1 2026.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.